1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Genzyme/Isis Build Simple, No Fuss Case For Weekly Cholesterol Injectable Kynamro

 
• By Emily Hayes

Genzyme and Isis are playing up mipomersen’s intrinsic qualities as they prepare to go head-to-head against Aegerion’s Juxtapid in the small homozygous familial hypercholesterolemia market. Kynamro also will carry a price tag that is $119,000 less than Juxtapid’s.

Ionis Pharmaceuticals Inc. and Genzyme Corp are counting on the convenient, simple dosing of their once-weekly subcutaneous injectable Kynamro as they prepare to launch against Aegerion Pharmaceuticals Inc.’s once-daily oral drug Juxtapid, with what they describe as an easy-to-use pre-filled syringe without the drug-drug interactions or need for nutritional supplements associated with Juxtapid.

FDA approved Kynamro (mipomersen) on Jan. 29 for homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering medications and diet in patients with HoFH to reduce LDL-C, apolipoprotein B, total...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

US ‘Most Favored Nations’ Drug Pricing Policy Will Jeopardize Innovation In Europe

 
• By Francesca Bruce

The US MFN executive order is the latest in a series of concerning US developments that are contributing to uncertainty for the European pharmaceutical industry, according to France Biotech’s vice president, Alexandre Regniault.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By Lisa Takagi

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.

GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By Cathy Kelly

For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.

Could EU Collective Procurement Counter US Most Favored Nation Policy?

 
• By Francesca Bruce

Joint procurement, if used by member states to respond to potential pricing and access challenges caused by a US most favored nations pricing policy, would cause more uncertainty for pharmaceutical companies, warn industry representatives.

More from Market Access

Rocky Rollout Spells Trouble for Medicare Prescription Payment Plan

 
• By Lauren Flynn Kelly

Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.

PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says

 
• By Cathy Kelly

The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.

US FDA’s Familiar Drug Pricing To-Do List

 
• By Michael McCaughan

President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.